Disodium Cromoglicate(インタ-ル)2%点鼻液剤による鼻アレルギ-の治療-2-二重盲検試験

概要

論文の詳細を見る
The effect of 2% nasal solution of disodium cromoglicate (DSCG) was investigated in a joint doubleblind study carried out at 10 hospitals, in 160 patients with perennial nasal allergy. The effectiveness and safety of the compound were studied and compared with those of placebo. The test solution was sprayed 1 squeeze per nostril, six times daily, for four weeks.DSCG was significantly superior to the placebo; three subjective dominant symptoms in nasal allergy, sneezing, watery discharge and nasal blockage almost equally improved, and also objective parameters such as swelling and colour of the mucous membrane, volume and characteristics of watery discharge, nasal provocative reaction and eosinophils in nasal smear improved. Global improvement rating with DSCG was 79.7% after two weeks of treatment and 91.7% after four weeks.The effect of DSCG appeared as early as the first week in 53.2% of the patients and was maintained for at least two weeks after discontinuation.The above effect was confirmed by the global assessment of the doctors, the patient's judgement, analysis of diary cards and by combined judgement according to fixed criteria. DSCG was effective irrespective of background factors such as sex, age, type, severity, dominant allergen, complementary allergen, duration of disease, history of disease, history of treatment, season, reactivity in nasal provocation and skin test, eosinophils in nasal smear and rhinoscopic findings.As side effects, nasal irritation, headache and epistaxis were observed in 6.8% of the patients. All of the symptoms were mild and transient, and did not require discontinuation of treatment.DSCG solution seems to be equally as effective as the powder form and is more easily applied than the powder form, particularly in young children.
耳鼻咽喉科臨床学会の論文

Disodium Cromoglicate(インタ-ル)2%点鼻液剤による鼻アレルギ-の治療-2-二重盲検試験

スポンサーリンク

概要

著者

関連論文

スポンサーリンク